MEAI

Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application.

Retrieved on: 
Friday, May 26, 2023
MDAI, Therapy, MEAI, PTSD, PCT, MDE, Literature, Patent, Post-traumatic stress disorder, Patient, USE, MBDB, Empathy, Terran, SALTS, MDMA, MDEA, Pharmaceutical industry

MDMA is the most studied empathogen to date and has been shown to be an effective treatment for post-traumatic stress disorder (PTSD) in multiple phase 3 trials.

Key Points: 
  • MDMA is the most studied empathogen to date and has been shown to be an effective treatment for post-traumatic stress disorder (PTSD) in multiple phase 3 trials.
  • Historically, MDMA has only been developed as a single salt and the crystal structures of its enantiomers had not been characterized.
  • As previously reported, Terran found that the S enantiomer of MDEA had significant advantages over the (R)-MDEA in preclinical models.
  • Terran is also developing the S enantiomer of MBDB which was shown to have significant advantages over (R)-MBDB in preclinical models.

Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder

Retrieved on: 
Monday, May 22, 2023
Mount Sinai Beth Israel, Medical school, CSE, Therapy, Yale School of Medicine, Clinical trial, MEAI, FSE, Research, Yale school, Mount Sinai, IP, Assistant, Ethics committee, AUD, Crave, MD, Patient, CWY, FIH, Phase, Safety, Substance abuse, Pharmaceutical industry, Psychiatry, Medicine

Yale School of Medicine’s Department of Psychiatry is the first US-based clinical site to join the company's first-in-human (FIH) trial.

Key Points: 
  • Yale School of Medicine’s Department of Psychiatry is the first US-based clinical site to join the company's first-in-human (FIH) trial.
  • The site will be led by Anahita Bassir Nia, MD, a specialist in substance abuse, including alcohol abuse.
  • The CM-CMND-001 clinical trial is a multinational, multi-center, Phase I/II single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects.
  • The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period.

Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

Retrieved on: 
Wednesday, May 17, 2023
Business development, Obesity, CSE, Therapy, Metabolism, Drug development, MEAI, FSE, Associate, Hebrew language, Metabolic syndrome, CWY, Pharmaceutical industry, Pharmacology

Tel Aviv, Israel / Vancouver, Canada, May 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, will host a virtual investor conference titled “Psychedelics for Obesity” on Monday, June 12th, at 10:00 AM EST.

Key Points: 
  • The conference will stream live on Monday, June 12, at 10:00 AM EST
    Tel Aviv, Israel / Vancouver, Canada, May 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, will host a virtual investor conference titled “Psychedelics for Obesity” on Monday, June 12th, at 10:00 AM EST.
  • Clearmind recently announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome.
  • Professor Tam will headline the conference discussing the challenges of obesity and the promising pre-clinical results for MEAI as a potential treatment.
  • The conference will also feature Mark Haden, Clearmind's VP of Business Development, and will be hosted by Shannon Smadella of Clearmind’s Community Development department.

Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder

Retrieved on: 
Friday, May 12, 2023
Institutional review board, Human, Sheba Medical Center, CSE, Therapy, Clinical trial, MEAI, FSE, Research, IMCA, Privacy, USD, Ethics committee, Committee, AUD, Crave, Ethics, Patient, IRB, CWY, Death, Safety, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, May 12, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has received Ethics Committee approval for its CM-CMND-001 Phase I/II clinical trial of its MEAI-based CMND-100 compound for the treatment of alcohol use disorder ("AUD") at Israel’s IMCA center.

Key Points: 
  • CM-CMND-001 is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic Study of CMND-100 in healthy volunteers and AUD subjects.
  • The company intends to have two additional sites in the United States, for this study, subject to signing an agreement with local sites.
  • The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period.
  • “Ethics Committee approval of the study marks a key step forward in beginning the first-in-human clinical trial of CMND-100," said Clearmind’s Chief Executive Officer, Dr. Adi Zuloff-Shani.

SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression

Retrieved on: 
Friday, April 21, 2023
Psilocybin, Patent, DMT, Obesity, CSE, Central nervous system, Depression, Therapy, Lysergic acid diethylamide, United States Patent and Trademark Office, MEAI, FSE, Ibogaine, LSD, DSM-IV codes, Palmitoylethanolamide, TEL, PEA, CWY, Ketamine, MDMA, Pharmaceutical industry

TEL AVIV, Israel, April 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, an additional provisional patent application was filed by Clearmind with the United States Patent and Trademark Office (“USPTO”).

Key Points: 
  • TEL AVIV, Israel, April 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, an additional provisional patent application was filed by Clearmind with the United States Patent and Trademark Office (“USPTO”).
  • The latest patent application refers to the protection of the unique combination of MEAI and SciSparc's Palmitoylethanolamide (“PEA”) for the treatment of depression.
  • Under this collaboration, three other patent applications have been filed by Clearmind with the USPTO for the combination of SciSparc’s PEA with Clearmind’s MEAI compound (5-methoxy-2-aminoindane) for the treatment of alcohol use disorder, treatment of cocaine addiction and treatment of obesity and its related metabolic disorders.
  • An additional six patent applications have been filed for the combination of SciSparc's PEA and lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT), 3,4 methylenedioxymethamphetamine (MDMA), ibogaine and ketamine.

Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression

Retrieved on: 
Friday, April 21, 2023
Patent, CSE, Depression, Obesity, Therapy, United States Patent and Trademark Office, MEAI, FSE, DSM-IV codes, PEA, Patient, CWY, Myenteric plexus, Safety, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, April 21, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces the filing of a patent application seeking to protect its unique combination of MEAI and SciSparc's Palmitoylethanolamide (PEA) for the treatment of depression.

Key Points: 
  • The company filed a provisional patent application with the United States Patent and Trademark Office (USPTO) as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat central nervous system disorders.
  • This patent is an addition to Clearmind's robust intellectual property portfolio that includes patents for MEAI as a binge behavior regulator, as an alcoholic beverage substitute and others.
  • The patent application refers to novel proprietary combinations of MEAI and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™.
  • Clearmind has a broad IP footprint in the psychedelic space with 24 patents in 14 patent families, nine of which have been granted in major jurisdictions like the US, Europe, China, and India.

Clearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial

Retrieved on: 
Thursday, April 20, 2023
Data management, CSE, Therapy, Clinical trial, MEAI, FSE, Alcoholism, AUD, CWY, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, April 20, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced additional preparations to facilitate the commencement of the company's clinical trial and engaged a contract research organization (CRO) to provide support for the company.

Key Points: 
  • Tel Aviv, Israel / Vancouver, Canada, April 20, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced additional preparations to facilitate the commencement of the company's clinical trial and engaged a contract research organization (CRO) to provide support for the company.
  • The CRO will act as a project manager, provide support in regulatory affairs, site selection and initiation, recruitment support, clinical monitoring, data management and more.
  • The company's upcoming first-in-human clinical trial will evaluate the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD).
  • “We are thrilled to continue moving forwards towards our first-in-human clinical trial,” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer.

Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder

Retrieved on: 
Thursday, March 16, 2023
AUD, FSE, Norepinephrine, Mevalonate pathway, SERT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, D-8 Organization for Economic Cooperation, Reward, MEAI, NET, Patient, Azerbaijan and Organization for Economic Co-operation, Parity, National Survey on Drug Use and Health, Death, Woman, Dopamine, CWY, FDA, Container deposit legislation in the United States, Clinical trial, Investigational New Drug, Food, Therapy, IND, Serotonin, DAT, CSE, Pharmaceutical industry, Health, Development

Tel Aviv, Israel / Vancouver, Canada, March 16, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has submitted an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA"), requesting approval to initiate its first-in-human Phase I/IIa clinical trial with CMND-100 in patients suffering from alcohol use disorder ("AUD"). Pending regulatory approval, the company plans to initiate the CMND-100 trial in Q2 2023.

Key Points: 
  • MEAI was found to interact with the serotonergic receptors 5-HT1a, 5-HT2a and 5-HT2b.
  • The serotonergic system is considered to play a key role in the regulation of alcohol intake, reward, preference, and dependence.
  • The IND submission to FDA, to initiate our clinical trial, is a milestone showing the huge commitment of the Clearmind team to finding a solution to this abusive disorder.
  • The economic loss results from missing labor days, resulting diseases, and other consequences of excessive alcohol use.

Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US

Retrieved on: 
Wednesday, February 15, 2023
Patent, PEA, Lysergic acid diethylamide, CWY, Therapy, United States Patent and Trademark Office, MEAI, Safety, Obesity, Patient, LSD, Psilocybin, DMT, FSE, Central nervous system, DSM-IV codes, CSE, Doctor of Philosophy, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has filed three provisional patent applications with the United States Patent and Trademark Office (USPTO) as part of its ongoing collaboration with pharmaceutical company SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc").

Key Points: 
  • The patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT) and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™.
  • SciSparc is a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.
  • Clearmind has a broad IP footprint in the psychedelic space with 23 patents in seven patent families, nine of which have been granted in major jurisdictions like the US, Europe, China, and India.
  • The company has already filed patent applications for the combination of Clearmind's MEAI with SciSparc's PEA compound for treating alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.

Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

Retrieved on: 
Wednesday, February 8, 2023
Obesity, FSE, Hebrew language, Metabolic syndrome, CWY, Drug development, Therapy, Metabolism, MEAI, Business development, CSE, Associate, Pharmaceutical industry, Pharmacology

Tel Aviv, Israel / Vancouver, Canada, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, will host a virtual investor conference titled “Psychedelics for Obesity” on Tuesday, February 28th, at 8:30 AM EST.

Key Points: 
  • Clearmind recently announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome.
  • The study was led by Professor Joseph Tam, D.M.D., Ph.D., head of the Obesity and Metabolism Laboratory and Associate Professor of Pharmacology at the Hebrew University’s Institute for Drug Research.
  • Professor Tam will headline the conference discussing the challenges of obesity and the promising pre-clinical results for MEAI as a potential treatment.
  • The conference will also feature Mark Haden, Clearmind's VP of Business Development, and will be hosted by Shannon Smadella of Clearmind’s Community Development department.